Mortality in patients treated with intravitreal bevacizumab for age-related macular degeneration
Abstract Background The aim of this study is to analyze mortality in patients treated with bevacizumab for wet AMD. Methods We conducted a retrospective case-control study between patients who received intravitreal injections of bevacizumab as the sole treatment for exudative AMD between September 2...
Main Authors: | , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2017-10-01
|
Series: | BMC Ophthalmology |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s12886-017-0586-0 |
id |
doaj-6d2fe18636494bacab1c39ddec10d7a9 |
---|---|
record_format |
Article |
spelling |
doaj-6d2fe18636494bacab1c39ddec10d7a92020-11-25T01:32:37ZengBMCBMC Ophthalmology1471-24152017-10-011711610.1186/s12886-017-0586-0Mortality in patients treated with intravitreal bevacizumab for age-related macular degenerationJoel Hanhart0Doron S. Comaneshter1Yossi Freier Dror2Shlomo Vinker3Department of Ophthalmology, Shaare Zedek Medical CenterCentral HeadquartersMashav Applied ResearchCentral HeadquartersAbstract Background The aim of this study is to analyze mortality in patients treated with bevacizumab for wet AMD. Methods We conducted a retrospective case-control study between patients who received intravitreal injections of bevacizumab as the sole treatment for exudative AMD between September 2008 and October 2014 (n = 5385) and age and gender matched controls (n = 10,756). All individuals included in the study were reviewed for sociodemographic data and comorbidities. Survival analysis was performed using adjusted Cox regression, using relevant adjusted variables. Results During follow-up (maximum: 73 months), 1063 (19.7%) individuals after bevacizumab died compared with 1298 (12.1%) in the control group (P < .001). After adjusted Cox survival regression, mortality differed significantly between the groups, Odds ratio = 1.69, (95% C.I. 1.54–1.84), P < .001. Conclusions We found an increased long-term mortality in individuals with wet AMD treated with bevacizumab compared to a same age and gender group without wet AMD.http://link.springer.com/article/10.1186/s12886-017-0586-0Neovascular AMDAnti-VEGFBevacizumabSafetyMortality |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Joel Hanhart Doron S. Comaneshter Yossi Freier Dror Shlomo Vinker |
spellingShingle |
Joel Hanhart Doron S. Comaneshter Yossi Freier Dror Shlomo Vinker Mortality in patients treated with intravitreal bevacizumab for age-related macular degeneration BMC Ophthalmology Neovascular AMD Anti-VEGF Bevacizumab Safety Mortality |
author_facet |
Joel Hanhart Doron S. Comaneshter Yossi Freier Dror Shlomo Vinker |
author_sort |
Joel Hanhart |
title |
Mortality in patients treated with intravitreal bevacizumab for age-related macular degeneration |
title_short |
Mortality in patients treated with intravitreal bevacizumab for age-related macular degeneration |
title_full |
Mortality in patients treated with intravitreal bevacizumab for age-related macular degeneration |
title_fullStr |
Mortality in patients treated with intravitreal bevacizumab for age-related macular degeneration |
title_full_unstemmed |
Mortality in patients treated with intravitreal bevacizumab for age-related macular degeneration |
title_sort |
mortality in patients treated with intravitreal bevacizumab for age-related macular degeneration |
publisher |
BMC |
series |
BMC Ophthalmology |
issn |
1471-2415 |
publishDate |
2017-10-01 |
description |
Abstract Background The aim of this study is to analyze mortality in patients treated with bevacizumab for wet AMD. Methods We conducted a retrospective case-control study between patients who received intravitreal injections of bevacizumab as the sole treatment for exudative AMD between September 2008 and October 2014 (n = 5385) and age and gender matched controls (n = 10,756). All individuals included in the study were reviewed for sociodemographic data and comorbidities. Survival analysis was performed using adjusted Cox regression, using relevant adjusted variables. Results During follow-up (maximum: 73 months), 1063 (19.7%) individuals after bevacizumab died compared with 1298 (12.1%) in the control group (P < .001). After adjusted Cox survival regression, mortality differed significantly between the groups, Odds ratio = 1.69, (95% C.I. 1.54–1.84), P < .001. Conclusions We found an increased long-term mortality in individuals with wet AMD treated with bevacizumab compared to a same age and gender group without wet AMD. |
topic |
Neovascular AMD Anti-VEGF Bevacizumab Safety Mortality |
url |
http://link.springer.com/article/10.1186/s12886-017-0586-0 |
work_keys_str_mv |
AT joelhanhart mortalityinpatientstreatedwithintravitrealbevacizumabforagerelatedmaculardegeneration AT doronscomaneshter mortalityinpatientstreatedwithintravitrealbevacizumabforagerelatedmaculardegeneration AT yossifreierdror mortalityinpatientstreatedwithintravitrealbevacizumabforagerelatedmaculardegeneration AT shlomovinker mortalityinpatientstreatedwithintravitrealbevacizumabforagerelatedmaculardegeneration |
_version_ |
1725080908471468032 |